www.pharmadynamics.co.za NEW CombAT INCONVENIENCE The 4-year CombAT study provides support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate to severe LUTS* due to BPH and prostatic enlargement1. *LUTS – Lower urinary tract symptoms INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IMPROVE QUALITY OF LIFE Duozaq 0,5 mg/0,4 mg. Each capsule contains 0,5 mg dutasteride and 0,4 mg tamsulosin as tamsulosin hydrochloride. S4 56/21.12/0796. For full prescribing information, refer to the professional information approved by SAHPRA July 2023.1. Roehrborn CG et. al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology 2010;57:123-131. DZQA1019/05/2024
RkJQdWJsaXNoZXIy NDIzNzc=